Technical Analysis for CLDX - Celldex Therapeutics, Inc.

Grade Last Price % Change Price Change
C 39.25 -3.96% -1.62
CLDX closed down 3.96 percent on Friday, April 12, 2024, on 49 percent of normal volume.
Earnings due: May 2
*** please verify all earnings dates ***
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Multiple of Ten Bearish Other 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Lower Bollinger Band Touch Weakness 0.00%
20 DMA Resistance Bearish -3.96%
50 DMA Resistance Bearish -3.96%
Bollinger Band Squeeze Range Contraction -3.96%
Multiple of Ten Bullish Other -3.96%
BB Squeeze + Lower Band Touch Range Contraction -3.96%

   Recent Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Celldex Therapeutics, Inc. Description

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused precision targeted immunotherapy platform. Its lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma and a Phase II study for the treatment of recurrent glioblastoma; and CDX-011, an antibody-drug conjugate, which completed a randomized Phase IIb study for the treatment of advanced breast cancer. The company also has various earlier stage candidates in clinical development, such as CDX-1135, a molecule that inhibits a part of the immune system called the complement system; CDX-1127, a therapeutic fully human monoclonal antibody for cancer indications that is in Phase I study in patients with selected malignant solid tumors or hematologic cancers; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor, which completed Phase I study in healthy subjects; and CDX-1401, an antibody-targeted technology program for cancer indications that completed Phase I study in combination with toll-like receptor agonists poly-ICLC. Its preclinical product candidate includes CDX-014, a human monoclonal antibody-drug conjugate that targets TIM-1, a molecule that is expressed on renal and ovarian cancers with minimal expression in normal tissues. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Thomas Jefferson University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Immunology Solid Tumors Immune System Immunotherapy Clinical Development Cancer Treatment Treatment Of Cancer Monoclonal Antibodies Monoclonal Antibody Breast Cancer Genetics Ovarian Cancer Treatment Of Breast Cancer Blastoma Glioblastoma Brain Tumor Antibody Drug Conjugate Cancer Center Complement System Cancer Research Pivotal Hematologic Cancers Advanced Breast Cancer Targeted Immunotherapy Dendritic Cell

Is CLDX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 53.18
52 Week Low 22.11
Average Volume 1,017,844
200-Day Moving Average 34.19
50-Day Moving Average 41.72
20-Day Moving Average 40.84
10-Day Moving Average 40.20
Average True Range 2.01
RSI (14) 41.86
ADX 11.38
+DI 21.36
-DI 22.34
Chandelier Exit (Long, 3 ATRs) 41.48
Chandelier Exit (Short, 3 ATRs) 44.12
Upper Bollinger Bands 42.73
Lower Bollinger Band 38.95
Percent B (%b) 0.08
BandWidth 9.25
MACD Line -0.86
MACD Signal Line -0.68
MACD Histogram -0.1769
Fundamentals Value
Market Cap 2.15 Billion
Num Shares 54.7 Million
EPS -2.65
Price-to-Earnings (P/E) Ratio -14.81
Price-to-Sales 476.60
Price-to-Book 8.43
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 42.70
Resistance 3 (R3) 42.85 41.86 42.13
Resistance 2 (R2) 41.86 40.98 41.78 41.93
Resistance 1 (R1) 40.55 40.44 40.06 40.40 41.74
Pivot Point 39.56 39.56 39.31 39.48 39.56
Support 1 (S1) 38.25 38.68 37.76 38.10 36.76
Support 2 (S2) 37.26 38.14 37.18 36.57
Support 3 (S3) 35.95 37.26 36.38
Support 4 (S4) 35.80